WA
ARKG icon

Win Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Win Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-75
Closed -$2K – 137
2022
Q3 		$2K Hold
75
– – ﹤0.01% 120
2022
Q2 		$2K Hold
75
– – ﹤0.01% 149
2022
Q1 		$3K Sell
75
-65,892
-100% -$3.14M ﹤0.01% 164
2021
Q4 		$4.04M Buy
+65,967
New +$4.56M 0.93% 24

Other funds holding ARKG

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Win Advisors's ARKG Position: Q4 2022 in Review

Win Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2022, closing a stake of 75 shares — an estimated $2K sold.

Win Advisors first reported a position in ARKG in Q4 2021 and held it in 4 quarters. The position peaked at $4.04M in Q4 2021. 319 funds tracked by Wall St. Rank hold ARKG as of Q4 2022.

  • Win Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2022 after selling out during the quarter.
  • Win Advisors sold 75 ARK Genomic Revolution ETF shares in Q4 2022, an estimated $2K.
  • Win Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 4 quarters.
  • Win Advisors's ARK Genomic Revolution ETF position peaked at $4.04M in Q4 2021.
  • 319 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2022.

Based on Win Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.